Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Trial BP-57

Clinical Breast Cancer

Volumn 5, Issue 3, 2004, Pages 208-215

  Smith, Roy E ^a   Anderson, Stewart J ^a   Lembersky, Barry C ^a   Brown, Ann ^a   Mamounas, Eleftherios P ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

Anthracyclines; Cardiac toxicity; Febrile neutropenia; Growth factor support

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DYSPNEA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; GRANULOCYTOPENIA; HUMAN; INFECTION; LUNG EMBOLISM; LUNG TOXICITY; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; METASTASIS; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PREMEDICATION; SECONDARY PREVENTION; SENSORY DYSFUNCTION; SEPSIS; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 12344266899     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.024     Document Type: Article

References (31)

1. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87:1169-1175.
2. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 1995; 13:1152-1159.
3. Wilson WH, Berg S, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12:1621-1629.
4. Ravdin PM, Burris HA 3rd, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13:2879-2885.
5. Ten Bokkel, Huinink WW, Prove AM, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:527-532.
6. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:2886-2894.
7. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17:2341-2354.
8. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
9. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 2003; 22:4 (Abstract #12).
10. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel (taxotere) to preoperative doxorubicin and cyclophosphamide (AC): preliminary results from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27. J Clin Oncol 2003; 21:4165-4174.
11. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13:2688-2699.
12. Gehl J, Bosgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7:687-693.
13. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19:314-321.
14. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975.
15. Nabholtz JM, Falkson C, Campos D, et al. Doxorubicin and docetaxel (AT) is superior to standard doxorubicin and cyclophosphamide (AC) as 1st line CT for MBC: randomized phase III trial. Breast Cancer Res Treat 1999; 57(suppl):84a (Abstract #485).
16. Dieras V. Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology (Huntingt) 1997; 11:17-20.
17. Aihara T, Takatsuka Y, Itoh K, et al. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 2003; 64:124-130.
18. Vallejos CS, Carranza H, Fodor M, et al. Combination of Taxotere (T) and doxorubicin (a): a South American phase II study in first line treatment (TT) of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 19:107a (Abstract #415).
19. Muthalib A, Wang CH, Luna G, et al. Combination of Taxotere (T) and Doxorubicin (A): an Asian phase II study in first line treatment (TT) of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 19:122 (Abstract #473).
20. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10:553-560.
21. Itoh K, Sasaki Y, Fujii H, et al. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Clin Cancer Res 2000; 6:4082-4090.
22. Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Huntingt) 1997; 11:34-36.
23. Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:35a (Abstract #137).
24. Smith RE, Anderson S, Brown A, et al. Phase II trial of a doxorubicin, docetaxel, and cyclophosphamide triplet for locally advanced and metastatic breast cancer: results from NSABP BP-58. Clin Breast Cancer 2002; 3:333-340.
25. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:1218-1225.
26. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, IA: The Iowa State University Press, 1980:120-121.
27. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
28. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. New York: Springer-Verlag, 1997:109-114.
29. Sparano JA, O'Neill A, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000; 18:2369-2377.
30. Zeng S, Chen YZ, Fu L, et al. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 2000; 6:3766-3773.
31. D'Incalci M, Schuller J, Colombo T, et al. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 1998; 25:16-20.